ITT Population
N = 3451

FOLFOX-4
N = 1151

FOLFOX-4 + bevacizumab
N = 1155

XELOX + bevacizumab
N = 1145

Number of participants with sufficient material for gene expression analyses
N = 1256

91 excluded from analyses
67 Nanostring assay failure
12 with multiple samples

Biomarker Evaluable Population
N = 1165

103 excluded from analyses due to missing clinical annotation

Participants/samples included in the data analyses
(arms combined for analyses)
Total N = 1062
FOLFOX-4 = 343
FOLFOX-4 + Bevacizumab = 366
XELOX + Bevacizumab = 353